A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer

NCT06363084 · clinicaltrials.gov ↗
COMPLETED
Status
64
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Ruijin Hospital